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tn its fifteenth year, the Transcatheter Cardiovascular Ther-
peutics (TCT) Annual Meeting is one of the largest
atherings in interventional cardiology. This year’s session
rovided live case demonstrations of novel techniques and
herapies, results of several clinical studies, and an excellent
eview of topics of interest for practicing interventional
ardiologists. The meeting also afforded a venue for exten-
ive industry exhibits, and the role of various devices utilized
n interventions was prominent. We report the results of key
linical trials presented at the TCT meeting and discuss
heir clinical implications in addition to summarizing the
ew techniques/topics presented.
RUG-ELUTING STENTS AND RESTENOSIS THERAPY
iven the success of the sirolimus-eluting stent in prevent-
ng restenosis (1), considerable efforts are being directed
oward developing other drug-eluting stents (DES). Results
rom various studies with newer DES were presented at the
CT meeting.
AXUS-IV. The Pivotal, Prospective, Randomized Trial
f the Slow-rate Release Polymer-based Paclitaxel-eluting
AXUS Stent. Greg Stone, MD; Stephen G. Ellis, MD.
The TAXUS-IV study evaluated the effect upon reste-
osis of a stent that eluted the antiproliferative drug
aclitaxel. The investigators enrolled 1,326 patients under-
oing elective stenting, with single de novo lesions, 10 to 28
m in length, treatable with one stent in vessels 2.5 to 3.75
m in diameter. Patients were randomized to either a 1
g/mm2 slow-release paclitaxel-eluting Express (Taxus)
tent or a bare-metal Express stent (Boston Scientific,
atick, Massachusetts) and received clopidogrel for six
onths. Exclusion criteria included prior percutaneous
oronary intervention (PCI), planned atherectomy, myocar-
ial infarction (MI) within 72 h, excessive vessel tortuosity
r calcification, total occlusion, visible thrombus, bifurca-
ion lesion, or initial Thrombolysis In Myocardial Infarction
TIMI) 0/1 flow grade. The primary end point was the
ine-month rate of ischemia-driven target vessel revascular-
zation (TVR).
The two groups were similar in baseline clinical charac-
eristics, angiographic characteristics, the target vessel re-
ascularized, and acute angiographic results. Nine-month
From the Division of Cardiovascular Medicine, University of California, San Diego
chool of Medicine, San Diego, California.TManuscript received November 21, 2003; accepted December 2, 2003.VR and target lesion revascularization (TLR) rates were
.7% and 3.0% with the Taxus stent and 12.0% and 11.3%
ith the bare metal stent (relative risk [RR]  0.39 and RR
0.27, both p  0.0001), respectively. No difference
xisted between the two groups in cardiac death, MI, or
tent thrombosis at nine months. Significant RR reductions
f 70% to 80% in TLR were seen in most patient and lesion
ubgroups, including diabetics, smaller vessels, and longer
esions.
A total of 732 patients were prospectively enrolled to have
ine-month angiographic follow-up in TAXUS-IV, and
59 (76.4%) patients underwent angiography. The mean
iameter stenosis in the analysis segment (5 mm proximal
nd distal to stent edge) was 39.8% with the bare-metal
tent and 26.3% with the Taxus stent (p  0.0001). Binary
estenosis and in-stent late loss were 26.6% and 0.92 mm
ith the bare-metal stent and 7.9% and 0.39 mm with the
axus stent (both p  0.0001), respectively. Significant risk
eductions for angiographic restenosis were seen in diabet-
cs, in all lesion lengths, and in all vessel diameters with the
axus stent except for larger reference vessel diameters
3.0 mm) where the trend toward lower restenosis was not
tatistically significant (6.8% Taxus vs. 15.2% bare-metal
tent, p  0.10).
UTURE-I and -II. Single and Multicenter Evaluation of
he Bioabsorbable Polymer-based Everolimus-eluting
tent. Eberhard Grube, MD.
Preliminary safety and efficacy data for the antiprolifera-
ive compound everolimus (Novartis, Basel, Switzerland)-
luting Champion stents (Guidant, Temecula, California)
ere presented. A total of 106 patients were randomized to
n everolimus-eluting stent (48 patients) versus its bare-
etal counterpart (58 patients) in single de novo lesions of
18 mm length. In FUTURE-I, which enrolled 42 non-
iabetic patients with simple lesions at a single center, late
oss was 0.11 mm with the everolimus stent and 0.85 mm
ith the bare-metal stent (p  0.0001) at six months. In
UTURE-II, diabetics (26.6%) and patients with more
omplex lesions were enrolled, and six-month late loss was
.12 mm with the everolimus stent and 0.85 mm with the
are-metal stent (p  0.0001). Binary restenosis was absent
n the everolimus stent but noted in 19.4% of the bare-metal
tents (p  NS).
NDEAVOR-I. A Prospective Multicenter Pilot Trial of
he Phosphorylcholine-based ABT-578-eluting Stent. Ian
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February 18, 2004:684–90 TCT 2003 Annual Session HighlightsThis phase I safety study enrolled 100 patients with single
e novo lesions of 15 mm, which were treated with a
hosphorylcholine-based sirolimus analogue (ABT-578,
bbott Laboratories, Abbott Park, Illinois) eluting from a
obalt chromium Endeavor stent (Medtronic, Santa Rosa,
alifornia). Procedural success was 100%; 30-day major
dverse cardiac event (MACE) rate was 1% while four-
onth angiographic late loss was 0.33 mm.
CRIPPS-IV. Scripps Radiation to Inhibit Proliferation
ost Stenting. Paul S. Teirstein, MD.
The SCRIPPS-IV investigators compared 14 Gy (stan-
ard dosing) versus 17 Gy (21.4% higher dose) gamma
adiation to assess additional efficacy of the higher dose on
estenosis in 358 patients with in-stent restenosis. The
igher dose resulted in eight-month angiographic in-stent
estenosis of 26.6% versus 41.8% standard dose (p  0.01)
nd in-lesion restenosis of 38.4% versus 46.8% standard
ose (p  0.18). Subset analysis revealed that diabetics had
reduction in TVR from 48% to 17.2% (p  0.01) with the
igher dose and accounted for the entire reduction in TVR
or the study population.
mplications. TAXUS-IV was the most significant study
resented at the TCT meeting. The benefit of the
aclitaxel-coated stent in all lesion subtypes and patient
opulations including diabetics was clinically significant and
onsistent. Given the results of TAXUS-IV, clinicians will
e faced with important questions: Not only should all
atients receive a drug-eluting stent (DES), but which one?
oth the sirolimus-coated Cypher (Cordis, Miami Beach,
lorida) and paclitaxel-coated Taxus stents have demon-
trated dramatic benefits compared to their bare-metal
ontrol groups. As TLR rates in various lesion and patient
ubtypes are in the low single digits with both of these
tents, it will be difficult to prove superiority of one stent
ver the other. Therefore, other stent characteristics includ-
ng deliverability, visibility, side-branch access, balloon
verhang, and cost will become deciding factors in choosing
etween these stents. In our experience, the Taxus stent is
asier to deliver and has greater side-branch access com-
ared to the Cypher stent. However, the Cypher is more
isible, and late loss of 0.24 mm in the analysis segment
ith the Cypher stent (1) is lower than the 0.39 mm with
he Taxus stent, which may be relevant in the very small
essels. Pilot studies utilizing ABT-578 and everolimus-
luting stents appear promising, demonstrating low late loss
ndices. The future availability of new DES should result in
ignificant cost reductions. Therefore, once the major cur-
ent limitation of utilizing DES in all patients (i.e., cost) is
o longer a factor, the criteria determining DES use and
election will become the technically superior product and
he company providing better service and research. Further
tudies utilizing DES in bifurcation lesions, unprotected left
ain stenosis, acute MI, vein graft disease, long lesions, and
estenotic lesions are required. In the meantime, particular
aution must be exercised in utilizing DES in very high-risk resions like left main stenosis where a TLR rate of 19.3%
as been reported with the Cypher stent (2).
For healthcare systems in which a DES for every patient
s difficult to justify financially, the bare-metal stent group in
AXUS-IV demonstrated that 89% of the PCI population
ould be effectively treated with bare-metal stents. Newer
obalt chromium stents, such as Vision (Guidant) and
river (Medtronic), owing to their thinner stent struts, may
urther lower restenosis compared to stainless steel stents,
ut randomized clinical trial data are lacking. Brachytherapy
emains an excellent treatment option for in-stent restenosis
f non-DES. Although, results from the SCRIPPS-IV trial
upport a higher gamma radiation dose (17 Gy vs. 14 Gy),
he applicability of this finding to the current practice of
nterventional cardiology is limited. As beta-radiation sys-
ems are easier to use and maintain, and have comparable
esults to gamma radiation, practice patterns will continue
o favor them.
DJUNCTIVE PHARMACOTHERAPY DURING PCI
hough the recent focus in interventional cardiology has
rimarily been toward preventing restenosis with DES,
fforts have also been directed toward optimizing anticoag-
lant regimens and improving periprocedural outcomes.
he lingering question of glycoprotein (GP) IIb/IIIa inhib-
tor effect on restenosis, if any, continues to cloud the issue
f which antiplatelet and anticoagulant regimen is most
fficacious. Studies presented at the TCT meeting con-
rmed the safety of another anticoagulation regimen for
CI patients and ended the controversy of abciximab’s effect
n restenosis.
EPLACE-2 (six-month results). Randomized Evalua-
ion of PCI Linking Angiomax to Reduced Clinical
vents-2. A. Michael Lincoff, MD.
The REPLACE-2 study was a 6,010-patient noninferi-
rity clinical trial in which subjects undergoing elective or
rgent PCI (not primary PCI for acute MI) were random-
zed either to the direct thrombin inhibitor bivalirudin plus
rovisional abciximab or eptifibatide (used in 7.2% of
atients) or to heparin plus a GP IIb/IIIa inhibitor (abcix-
mab or eptifibatide). The primary quadruple composite end
oint of the 30-day incidence of death, MI, urgent repeat
evascularization, or in-hospital major bleeding was ob-
erved in 9.2% of the bivalirudin group and 10.0% of the
eparin plus GP IIb/IIIa inhibitor group (p  0.32) (3).
owever, the bivalirudin group had a nonsignificant higher
ate of MI at 30 days (7.0% vs. 6.2%, p  0.23) but with a
eduction in major bleeding events (2.4% vs. 4.1%, p 
.001).
Six-month data from REPLACE-2 demonstrated that
he rates of death (0.95% vs. 1.35%, p 0.15), MI (8.2% vs.
.4%, p  0.24), revascularization (12.1% vs. 11.4%, p 
.45), and TVR (9.8% vs. 8.7%, p  0.15) were similar in
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ilostazol vs. Ticlopidine in Patients Undergoing Stent
mplantation. Junbo Ge, MD.
Cilostazol is a platelet aggregation inhibitor shown to
educe neointimal proliferation and possibly restenosis. The
nvestigators randomized 397 patients to either ticlopidine
50 mg twice a day for one month or cilostazol 100 mg
wice a day for six months after elective coronary stenting to
valuate the effect of cilostazol on restenosis. The primary
nd point of angiographic restenosis at six months was
9.1% in the cilostazol group and 36.6% in the ticlopidine
roup (p  0.086).
SAR SMART-II. A Prospective, Randomized Four-arm
rial of Phosphorylcholine-coated Stenting  IIb/IIIa
nhibition vs. PTCA  IIb/IIIa Inhibition in Patients with
mall Coronary Arteries Undergoing PCI. Adnan Kastrati,
D.
The investigators, utilizing a 2  2 factorial design,
andomized 502 patients with small coronary arteries (2.5
m) to a phosphorylcholine-coated BiodivYsio SV stent
Abbott Vascular, Redwood City, California) versus balloon
ngioplasty, and abciximab versus placebo, to determine the
ffect of this stent and abciximab on restenosis in small
oronary arteries. Patients were pretreated with clopidogrel,
nd the groups were matched for baseline clinical and
ngiographic characteristics (average vessel diameter 2.2
m and 28% diabetics). The primary end point of angio-
raphic binary restenosis was 39.0% with stenting and
4.2% with balloon angioplasty (p  0.30) at six months,
hile TVR was 20.9% and 21.3% (p  0.93), respectively.
bciximab failed to reduce angiographic restenosis (39.3%
bciximab vs. 34.3% placebo, p  0.29) or TVR (19.9%
bciximab vs. 22.3% placebo, p  0.51). Secondary end
oints of one-year TVR, death, or MI were not favorably
ffected with either stenting or with abciximab.
mplications. The six-month results of REPLACE-2 are
eassuring in that the higher periprocedural MI rate with
ivalirudin does not lead to an increased six-month mortal-
ty. The absence of a significant difference in revasculariza-
ion rates between the two groups, in both diabetic and
ondiabetic patients, confirms the absence of GP IIb/IIIa
nhibitor effect on restenosis. It is important to note that in
EPLACE-2, patients with an acute coronary syndrome
reated with heparin or upstream GP IIb/IIIa inhibitor were
xcluded, and 86% (5,159/6,002) of the study cohort were
retreated with either clopidogrel or ticlopidine. Therefore,
he noninferiority of bivalirudin (with bailout GP IIb/IIIa
nhibitor) against heparin plus GP IIb/IIIa inhibitor, at 30
ays and six months, is only proven for stable patients
ndergoing PCI who have been pretreated with clopidogrel
r ticlopidine.
Results from the ISAR SMART-II trial demonstrate
hat at least in the presence of clopidogrel pretreatment,
here was no demonstrable benefit to abciximab or bare-
etal stenting on angiographic restenosis, TVR, or 30-day
ACE rates in small vessels. Given the high restenosis wates observed with balloon angioplasty and bare-metal
tents, studies are needed to determine whether small
oronary arteries are best treated with DES. The trend
oward lower restenosis with cilostazol in the RACTS trial
uggests that a larger study may be required to answer the
uestion of cilostazol’s effect on neointimal proliferation and
estenosis.
CUTE MYOCARDIAL INFARCTION
meta-analysis of 23 randomized clinical trials of primary
CI versus thrombolysis for the treatment of acute ST-
levation MI (STEMI) (4) concludes that primary PCI is
uperior in terms of death (7% vs. 9%, p 0.0002), nonfatal
einfarction (3% vs. 7%, p 0.0001), and stroke (1% vs. 2%,
 0.0004). However, primary PCI cannot be offered to
very patient owing to the low number of high-volume
perators and primary PCI centers. Because significant
yocardial necrosis occurs even with early primary PCI,
urrent efforts are being directed to evaluate adjunctive
echniques of myocardial salvage.
OOL-MI. A Prospective, Randomized Trial of Mild
ystemic Hypothermia During PCI Treatment of ST Ele-
ation MI. William W. O’Neill, MD.
This trial tested the safety, efficacy, and ability to enhance
yocardial salvage of systemic patient cooling as an adjunct
o primary PCI for STEMI. The investigators randomized
92 patients with anterior or inferior (with reciprocal
hanges) STEMI of6 h duration to either primary PCI or
rimary PCI with endovascular cooling (Radiant Medical,
edwood City, California) produced by a 10F endovascular
atheter placed in the inferior vena cava. The two groups
ere matched in baseline clinical and angiographic charac-
eristics except that door-to-balloon times were higher in
he cooling group (110 vs. 92 min, p 0.003). Cooling was
olerated in 94.3% of the cohort, although buspirone and
eperidine were required to control shivering. Analysis
evealed no difference in left ventricular infarct size (14.1%
ooling vs. 13.8% control, p 0.83) or 30-day MACE rates
6.2% cooling vs. 3.9% control, p 0.45) but did observe an
ncreased risk of shock in the cooling group (12.4% cooling
s. 6.1% control, p  0.06).
-AMINE ST. X-Sizer in Acute Myocardial Infarction
atients for Negligible Embolization and Optimal ST
esolution. Thiery Lefevre, MD.
Intracoronary thrombus with distal embolization is
hought to be partly responsible for no-reflow and poor
icrovascular perfusion after primary PCI for STEMI.
his study evaluated the benefit of mechanical throm-
ectomy with the X-Sizer catheter (ev3, Plymouth,
innesota) before primary PCI. Investigators random-
zed 201 patients with STEMI of 12 h in whom initial
ngiography demonstrated TIMI 0/1 flow grade in a
ative coronary artery. Baseline clinical and angiographic
haracteristics, GP IIb/IIIa inhibitor use, and stent use
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roup (7.5 mm vs. 4.95 mm, p  0.036). Secondary end
oint analysis revealed less slow flow/no-reflow (4.1% vs.
6.0%, p  0.012) and distal embolization (2.1% vs. 10%,
 0.006) in the thrombectomy group but with the
ddition of procedural time (55 vs. 45 min, p  0.003).
nterestingly, no differences in the final infarct artery
IMI frame count, percentage of patients with final
IMI-3 flow grade, or 30-day MACE rate between the
wo groups were noted.
N-TIME. Ongoing Tirofiban in Myocardial Infarction
valuation. Harry Suryapranata, MD.
Prehospital treatment of STEMI with the GP IIb/IIIa
nhibitor abciximab results in greater TIMI-3 flow at
nitial angiography, and improved 30-day left ventricular
unction and six-month clinical outcomes (5). This study
valuated the benefits of early precatheterization initia-
ion of the GP IIb/IIIa inhibitor tirofiban against late
n-laboratory initiation, as an adjunct to primary PCI for
TEMI. The investigators randomized 507 patients with
TEMI of 6 h undergoing primary PCI to early
ambulance or referral center) or late (cardiac catheter-
zation laboratory) tirofiban. The two groups were
atched for baseline characteristics, and the primary end
oint of TIMI-3 flow at initial angiography was noted in
9% of the early group and 15% of the late group (p 
.22). Secondary end points of visible thrombus at initial
ngiography (25% early vs. 32% late, p  0.06) and PCI
uccess as judged by postprocedural TIMI-3 flow, myo-
ardial blush scores, and corrected TIMI frame counts
ere also similar between the two groups.
mplications. Though tremendous hope had been placed
n systemic hypothermia as a useful adjunct to limit infarct
ize, the results of COOL-MI are disappointing. Despite
andomizing patients with large infarcts only, the investi-
ators were unable to demonstrate benefit of this therapy.
he inability to cool all patients to 33°F, as was the goal,
ay have been one limitation to the potential benefit of this
herapy. Hyperbaric oxygen, by inhibiting leukocyte adher-
nce, reducing tissue edema, limiting lipid peroxidation, and
ree radical formation, has been shown to reduce tissue
njury associated with ischemia/reperfusion (6). Studies are
ngoing to evaluate the benefit of intracoronary hyperox-
mic blood delivery after primary PCI for STEMI, and
reliminary data regarding infarct size reduction appears
ore promising than endovascular cooling.
Mechanical thrombectomy with the X-Sizer catheter led
o greater ST-segment resolution, lower incidence of distal
mbolization, and no-reflow, but this did not translate to a
ower 30-day MACE rate. This last finding is disappointing
nd raises the question of routine use of this device for all
TEMI patients. Limiting this device to patients with a
arge thrombus burden may translate the initial angio-
raphic benefits of this device into clinical benefits. Though
he failure of early administration of tirofiban for STEMI
ay be related to a suboptimal dose of tirofiban, the lN-TIME study does not support substantial benefit of
arly tirofiban initiation for STEMI.
ERIPHERAL VASCULAR DISEASE
ewer therapies and controversies regarding peripheral
ascular disease (PVD) treatments were discussed, and
ne-year results of an important clinical trial regarding
arotid stenting were presented.
APPHIRE (one-year results). Stenting and Angioplasty
ith Protection in Patients at High Risk for Endarterec-
omy. Jay Yadev, MD.
This multicenter study randomized 310 high-risk surgical
andidates to carotid stenting with the nitinol self-
xpanding Precise stent (Cordis) in conjunction with An-
ioguard (Cordis) distal embolic protection versus carotid
ndarterectomy (CEA). Symptomatic patients with a
reater than 50% internal carotid artery stenosis, or asymp-
omatic patients with a greater than 80% stenosis with all
atients having at least one high-risk co-morbidity for
EA, were randomized. The primary end point of 30-day
ajor adverse event (MAE  death, MI, and any cerebro-
ascular accident [CVA]) has been reported previously and
as 5.8% with stenting and 12.6% with CEA (p  0.047).
The secondary end point of 30-day MAE plus death and
psilateral CVA between 1 and 12 months was 11.9% with
tenting and 19.9% with CEA (p  0.048). No differences
n mortality or MI were seen at one year, but lower rates of
ajor ipsilateral stroke were noted after stenting. Clinically
riven TLR occurred in 0.6% of patients with stenting
ersus 4.0% with CEA (p 0.06), while cranial nerve injury
ccurred in 0.0% with stenting versus 4.6% with CEA, (p
.006).
mplications. The SAPPHIRE trial demonstrates the
oninferiority of carotid stenting to CEA for patients with
arotid artery stenosis and high-risk surgical features. The
arotid Revascularization Endarterectomy versus Stent
rial (CREST) is a NIH/Guidant-funded study that is
andomizing 2,500 low-risk patients to evaluate these two
trategies for carotid revascularization. Until the results of
he CREST trial are available, patient and physician pref-
rence is likely to dictate carotid stenting as the preferred
odality of carotid artery revascularization for patients with
igh-risk surgical features once reimbursement issues re-
arding this procedure are settled.
The treatment and limitations associated with endovas-
ular approaches to noncarotid PVD were discussed in
umerous sessions devoted to the subject. Iliac and subcla-
ian artery stenoses can be treated by endovascular tech-
iques with excellent short- and long-term outcomes. How-
ver, significant investigative efforts are ongoing to
etermine the optimal revascularization strategy for super-
cial femoral artery (SFA) disease. It has been suggested
hat nitinol, as opposed to stainless steel self-expanding
tents, has lower restenosis in the SFA. However, reports of
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TCT 2003 Annual Session Highlights February 18, 2004:684–90he clinical implications of this latter finding are unknown,
nd future clinical trials with DES in the SFA are under-
ay, which will help address the issue and also determine
estenosis rates with DES in the SFA. Percutaneous treat-
ent of infrapopliteal disease is primarily utilized for limb
alvage and as an adjunct for the treatment of nonhealing
lcers in the lower extremities.
Percutaneous stent placement (not balloon angioplasty)
ith 98% success and 2% complication rate is the treatment
f choice for renal artery stenosis. Though renal artery
tenosis is a progressive disease and is associated with
ncreased mortality in the presence of chronic renal insuf-
ciency, no well-designed clinical studies have proven that
reatment of a stenotic renal artery reduces mortality.
evertheless, acceptable indications for renal artery stenting
nclude bilateral renal artery stenosis with hypertension,
nstable angina, progressive renal insufficiency, or recurrent
ulmonary edema; or unilateral renal artery stenosis in
ypertensive patients with 70% stenosis, a kidney larger
han 7 cm, and a resistive index0.8 by Duplex ultrasound.
he future role of DES and distal embolic protection
evices for renal artery stenting remains to be defined.
EW DEVICES/TECHNIQUES/THERAPIES
omplex issues regarding newer techniques and devices for
reatment of the coronary vasculature, peripheral vascula-
ure, and structural heart disease were discussed.
omplex Coronary Anatomy
ifurcation lesions. The treatment of a bifurcation lesion
as been a long-standing problem in interventional cardi-
logy and remains difficult. A significant portion of the live
ase demonstrations focused on the treatment of bifurcation
esions using the “Crush Technique” (7), which was dem-
nstrated in multiple cases but was not always successful in
he hands of these high-volume operators. This technique
nvolves the placement of a DES in the side-branch vessel
nd this stent is pulled back at least 4 to 5 mm into the
arent vessel at the time of deployment (Fig. 1). The
ide-branch stent balloon and wire are then removed. A
econd DES is then deployed in the parent vessel and it
rushes the proximal 4 to 5 mm of the side-branch stent,
hich is in the parent vessel. At this point, only if the
ngiographic images in multiple projections reveal an unaccept-
ble result, the side-branch stent is recrossed, and kissing balloon
nflations are performed. Theoretically, this technique ensures
hat a DES covers the entire diseased segment in the parent
essel and side-branch. However, it is not always easy to
ecross into the side-branch with three layers of stent that
ave been opposed against the vessel wall. Furthermore, the
otential toxicity of the eluting drug at three times the
ecommended dose is unknown, and, most importantly, no
ong-term data regarding the efficacy of this approach were
resented. ahronic total occlusions. Suero et al. (8) have reported on
he long-term benefits of recanalizing chronic total occlu-
ions (CTOs). Of the various devices and techniques
resented, the FrontRunner (Lumend, Redwood City, Cal-
fornia) catheter seemed to be a particular favorite of
ultiple operators and successfully utilized for CTOs in
oth coronary arteries and peripheral vessels. It is a blunt
icrodissection tool that requires careful dissection into the
istal true lumen from the proximal true lumen. Although
he device is approved by the U.S. Food and Drug Admin-
stration (FDA), it should be reserved for situations in
hich other techniques have failed.
tructural Heart Disease
ercutaneous mitral valve repair/annular reshaping. Per-
utaneous mitral valve repair involves placement of stent-
ike devices in the coronary sinus that reshape and tighten
he mitral valve annulus by pushing the posterior leaflet
nteriorly. The risk of impinging on the circumflex coronary
rtery and thrombosis of the coronary sinus with this device
s unknown. Another approach presented was the percuta-
eous suture of the mid-portion of the anterior and poste-
ior leaflets of the mitral valve, creating a double-barreled
rifice of the valve. Animal studies with these devices appear
romising.
ercutaneous aortic valve replacement. This technique
as been described previously (9), and clinical data from the
nitial series were presented. Seven patients with critical
ortic stenosis, who were nonsurgical candidates owing to
o-morbid conditions, had a bovine bioprosthetic valve
ounted on a specially designed stent (Percutaneous Valve
echnologies, Fort Lee, New Jersey), which was placed
igure 1. Crush technique: stent positioning. The proximal marker of the
ide-branch stent (thin dashed line) must be situated in the main branch
t a distance of 4 to 5 mm proximally to the carina of the bifurcation. Thick
ashed line follows the main-branch stent. Adapted from Colombo et al.
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February 18, 2004:684–90 TCT 2003 Annual Session Highlightsular aortic regurgitation was noted in some patients, all
atients had a mean transvalvular gradient of 5 mm Hg 24 h
fter the procedure with a reduction in valvular stenosis and
n improvement in ejection fraction. The technique requires
urther refinement but appears promising.
atent foramen ovale closure. The primary limitation for
idespread patent foramen ovale (PFO) closure is the
aucity of data demonstrating the efficacy of this approach.
urrently, PFO closure can be carried out as a humanitarian
evice exemption for patients who suffer a recurrent cryp-
ogenic stroke despite anticoagulation therapy. Large ran-
omized clinical trials are finally underway that will com-
are outcomes of PFO closure against standard medical
herapy in patients who suffer a first-time cryptogenic
troke.
djunctive Interventional Devices
therectomy devices. The X-Sizer Thrombectomy Cath-
ter (ev3) is a disposable device designed to rotate, cut, and
spirate thrombotic material but is not FDA approved. For
emoral-popliteal and infrapopliteal disease, the SilverHawk
ystem (FoxHollow Technologies, Menlo Park, California)
s an FDA-approved device for de novo and restenotic
esions in the lower extremities. The catheter is placed in the
iseased segment and with activation of the cutter, plaque is
emoved and collected in the distal cone of the device. Both
alcified and noncalcified lesions in peripheral vessels 2 to 6
m in diameter can be treated. Studies utilizing this device
n the coronary vasculature are ongoing.
ercutaneous hemodynamic support. For patients in car-
iogenic shock who require PCI, or in patients with or
ithout left ventricular dysfunction who have only one
atent vessel and require PCI, intraaortic balloon pump
ounterpulsation is the most commonly used assistive de-
ice. The Impella®acute (Impella, Aachen, Germany) is a
2F left ventricular system that is inserted percutaneously
ia a 13F sheath in the femoral artery and has both a
roximal and distal port positioned within the proximal
orta and left ventricle, respectively. It actively unloads the
eft ventricle, enables a cardiac output of 2.5 l/min, can be
eft in place for five days, and could be utilized for acute MI,
ardiogenic shock, high-risk PCI, and a low output cardiac
tate. It is not yet FDA approved.
ulnerable plaque detection. Invasive modalities to detect
ulnerable plaque include the following: a thermography
atheter that is temperature sensitive and can detect higher
emperature plaques which may be vulnerable to rupture;
ntravascular ultrasound with differential measurement of
issue echogenicity; intravascular ultrasound palpography,
hich can determine ultrasonic backscatter from hard and
oft plaque, thus enabling assessment of plaque strain; and
ptical coherence tomography. Though all of these invasive
odalities appear useful, noninvasive modalities including
iomarkers, or computed tomography/magnetic resonance
maging that could identify the vulnerable patient rather
han plaque, seem more attractive. eistal embolic protection devices. Most of the newer
enerations of distal embolic protection devices are able to
apture both micro- and macro-particulate material while
nabling blood flow at the time of PCI. It is becoming
ncreasingly clear that saphenous vein graft interventions,
ative coronary artery interventions in both acute MI and
cute coronary syndromes, carotid stenting, and possibly
enal stenting should all be performed with distal embolic
rotection devices.
yogenesis/Angiogenesis
arious strategies for stem-cell implantation to help in
reservation and restoration of MI and treat myocardial
schemia were presented. Autologous stem-cell injections
re feasible, and stem cells can be injected intravenously,
nto the culprit coronary artery three to five days after
I, and epicardially or transendocardially into the myo-
ardium, with demonstration of homing of these cells to
ites of injury (10). Skeletal myoblasts may lead to
norganized muscle cell formation and serve as a source
f reentry and ventricular arrhythmias. Though proof of
rinciple has been demonstrated, extensive work is still
equired to evaluate concentration of stem-cell infusion,
oute of injection, methodology of gauging success, and
valuation of safety.
UMMARY
he results of several clinically relevant new trials and
ystematic overviews of current challenges facing interven-
ional cardiology were presented at the TCT meeting.
rug-eluting stents have revolutionized the field of inter-
entional cardiology, and restenosis, though not eliminated,
s now at an acceptable level. Adjunctive therapies, both
echanical and pharmacologic, for myocardial salvage dur-
ng PCI for acute coronary syndromes require ongoing
nvestigative effort. Percutaneous treatment of peripheral
ascular disease is in evolution, but in addition to improve-
ent in technology, indications for treatment need to be
etter defined. Stem-cell treatment of acute and chronic
yocardial ishemia and percutaneous strategies for the
reatment of structural heart disease appear promising.
lthough many live procedures were presented, the benefit
f live case demonstrations at interventional cardiology
eetings is becoming less clear. In the early days of this
iscipline, live demonstrations were often the only route of
xposure to new approaches and techniques. Currently,
nterventional cardiology is a mature specialty with broad
iffusion of knowledge, accredited training programs and a
pecialty requiring a board examination for certification.
herefore, future presentations of new techniques in the
orm of live demonstrations will need a clear rationale and
hould likely be confined to procedures for which clinical
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